



Table 1. EIPE-1 Inhibits Cryptococcus Growth
Cryptococcus cultures: C. neoformans strain H99 (serotype A) was grown for 18 hours at 30C with YPD broth in
a shaking incubator. The cells were collected by centrifugation and washed three times with sterile phosphate-
buffered saline (PBS), to remove any extra residue from the YPD broth. Fungal cells were quantified by trypan dye
exclusion using a hemocytometer.
MIC Assays with Amphotericin B or EIPE-1. C. neoformans were suspended in RPMI with MOPS, 0.165M, at a
concentration of 0.5×103 cells/ml. RPMI MOPS media was added to a 96-well plate in a volume of 100µL in each
well, with the exception of the column containing the highest concentration of drug Amphotericin B or EIPE-1 was
added at a concentration of 100 mg/µl and serially diluted 1:2. Control wells included one row with only RPMI
MOPS media. C. neoformans was added to all wells at a volume of 100 µl per well, so the final volume of the wells
was 200 µL. Plates were incubated at 35°C in a humid incubator for 48 hrs. Data were analyzed visually and by
reading ODs at 490nm on a platereader (BioTek).
RAW macrophage cell culture: Immortalized RAW macrophages (ATCC) were grown in RAW cell culture media
(DMEM + 10% heat-inactivated fetal bovine serum) per manufacturer’s instructions. Cells were incubated at 37C,
5% CO2 in T75 tissue culture flasks and passaged twice per week.
Antifungal activity of EIPE-1 with Cryptococcus and RAW macrophages: The RAW macrophages were split
and counted before the experiment. RAW macrophages and C. neoformans were counted and adjusted in RAW
media and added to 96-well plates at 2×105 per well for macrophages and 1×104 per well for C. neoformans. Anti-
GXM opsonizing antibody was also added to each well. The 96-well plate was incubated at 37C, 5% CO2 for 24
hours. A portion of the inoculum was set aside for diluting and plating on YPD agar, followed by incubation at 30C
for 2 days, followed by quantification of the inoculum CFU. Following 24h incubation of the C. neoformans with
RAW macrophages, plates were centrifuged and the supernatant was discarded, while a pellet was left at the bottom.
100µl of sterile cell culture grade water was added to each well to lyse the macrophages for 15 minutes at room
temperature. Contents of the wells were serially diluted and plated on YPD agar. The plates were incubated at 30C
for 2 days and then CFU were counted.
Antifungal activity of EIPE-1 with Cryptococcus and RAW macrophages following 2-hour phagocytosis: To
determine if EIPE-1 could penetrate the RAW macrophages after phagocytosis of C. neoformans, the RAW
macrophages, C. neoformans, and opsonizing antibody were incubated as described above for 2h. Following this
incubation, EIPE-1 was added for an additional 24h, followed by diluting and plating for CFU.
Data analysis: The inoculum plates and experiment plates were counted and CFU were determined. Prism software
was used to generate graphs and for statistical analyses. For these studies, ANOVA with a Tukey’s post-test (to
compare all pairs) was conducted to determine statistically significant differences (p<0.05).
Figure 1. EIPE-1 has Antifungal Activity Against
C. neoformans During Macrophage Co-culture
Methods
Cryptococcus neoformans is an opportunistic fungal pathogen of the respiratory tract, which is responsible
for over 200,000 deaths annually. Antifungal drugs have been used to treat fungal infections for many
decades; however, due to similarities between fungal and mammalian cells, these drugs are often toxic. In
these last few decades, the fungi have also become resistant to the antifungal drugs. EIPE-1 was
synthesized from vanillin, and was shown to have activity against methicillin resistant S. aureus (MRSA),
and other gram-positive bacterial pathogens. We hypothesized that EIPE-1 could be used to kill fungal
pathogens. For this study, we tested EIPE-1 against C. neoformans using a minimum inhibitory
concentration (MIC) assay and an in vitro model of intracellular macrophage growth using RAW
macrophages. EIPE-1 has antifungal activity in our MIC assay, with an MIC value of 1.749 µg/ml. In
addition, after incubation of C. neoformans with RAW macrophages and EIPE-1, treatment with EIPE-1
had significant antifungal effects on C. neoformans compared to C. neoformans alone and compared to C.
neoformans with RAW macrophages. In further studies, we will examine the mechanism of EIPE-1 anti-
fungal activity, and we will also test EIPE-1 against other fungal pathogens including Candida albicans.
Abstract
Cryptococcus neoformans is an opportunistic fungal pathogen that is acquired through inhalation, but can
disseminate to the brain to cause meningitis. C. neoformans infects patients with immune deficiencies such
as AIDS, chemotherapy patients, and those on immune suppressive drugs. It can cause meningitis, which
has a 40% mortality rate, even after treatment with antifungal drugs. Each year, there are 200,000 reported
cases of cryptococcal meningitis and nearly 181,000 deaths each year worldwide. In spite of the many
advances in antifungal therapies, the antifungal drugs that are available now have high toxicity. In addition,
the fungal organisms have begun to acquire resistance to the antifungal drugs that are currently being used
today. As a result, there is a limited ability for the regulation of life-threatening infections, especially for
individuals that are immunocompromised. To address this issue, a eumelanin-inspired compound, EIPE-1,
which is derived from vanillin was synthesized. This synthetic compound was tested against drug-resistant
bacteria, and it has demonstrated antimicrobial effects on methicillin-resistant S. aureus (MRSA), but not
on gram-negative organisms. In this study, we first determined the effects of EIPE-1 against the fungal
pathogen C. neoformans in a minimum inhibitory concentration assay. Next, because C. neoformans is
thought to traffic from the lungs to the brain inside of macrophages, we tested the efficacy of EIPE-1
during macrophage phagocytosis of C. neoformans to determine whether EIPE-1 could be used
therapeutically
Conclusion: Incubation of C. neoformans with RAW macrophages and
EIPE-1 for 24h led to significant inhibition of growth compared to C.
neoformans grown alone (p<0.05). Data shown are from three experiments,
with each condition conducted in triplicate.
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Figure 2. EIPE-1 has Antifungal Activity Against C. 

































Conclusion: EIPE-1 inhibits the growth of C. neoformans, with a
minimum inhibitory concentration (MIC) of 1.749 µg/ml compared to an
MIC of 0.682 µg/ml with the antifungal drug Amphotericin B. Data shown
are from 7 experiments with EIPE-1 and 4 experiments with Amphotericin
B.
Conclusion: EIPE-1 has significant antifungal activity against C. neoformans
after 2 hour phagocytosis by RAW macrophages compared to C. neoformans
grown in media alone (p<0.05). Data are shown from two experiments, with each
condition conducted in triplicate.
Future Directions
• Conduct EIPE-1 antifungal studies with another fungal pathogen, Candida 
albicans
• MIC assays, RAW macrophage assays
• Identify the antifungal mechanism of action EIPE-1 on  fungal pathogens
• Collect RNA form EIPE-1 treated fungal pathogens
- Conduct RNA-sequencing experiments to identify fungal 
genes affected following EIPE-1 treatment
• EIPE-1 is effective at inhibiting the growth of C. neoformans in the MIC assay
• EIPE-1 is effective at inhibiting the growth of C. neoformans during 
incubation with RAW macrophages
• EIPE-1 is effective at inhibiting the growth of C. neoformans after 
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